文献速递骨软组织肉瘤与黑色素瘤

CDCA2通过抑制Aurora激酶A的泛素化降解促进黑色素瘤进展

CDCA2 promotes melanoma progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A.
PubMed 文献 · Eur J Cancer · 2023-04-20

该研究检测了黑色素瘤与良性黑色素细胞痣组织中CDCA2的表达,并在体外和体内模型中敲低或过表达CDCA2以评估其对黑色素瘤细胞表型和肿瘤生长的影响。研究发现CDCA2在黑色素瘤组织中高表达且与肿瘤分期和不良预后正相关;机制上CDCA2通过作用于SMAD特异性E3泛素蛋白连接酶1抑制泛素依赖性AURKA蛋白降解,从而促进黑色素瘤进展。

要点

  • CDCA2在黑色素瘤组织中高表达,且CDCA2水平与肿瘤分期和不良预后正相关。
  • CDCA2下调通过诱导G1/S期阻滞和凋亡显著减少细胞迁移和增殖,并在体内抑制肿瘤生长和Ki67表达。
  • CDCA2通过抑制SMAD特异性E3泛素蛋白连接酶1介导的AURKA泛素化增强AURKA蛋白稳定性,发挥致癌作用。

核心结论

  • CDCA2在黑色素瘤中上调,通过抑制SMAD特异性E3泛素蛋白连接酶1介导的AURKA泛素化增强AURKA蛋白稳定性,从而在黑色素瘤进展中发挥致癌作用。

研究设计与样本

  • 研究采用基因芯片和生物信息学分析以及免疫组化检测黑色素瘤样本与良性黑色素细胞痣组织中CDCA2的表达。
  • 采用定量PCR检测系统和Western blot检测黑色素瘤细胞中的基因表达。
  • 体外构建基因敲低或过表达的黑色素瘤模型,并通过Celigo细胞计数、Transwell、伤口愈合、流式细胞术和皮下裸鼠肿瘤模型评估基因敲低或过表达对黑色素瘤细胞表型和肿瘤生长的影响。
  • 采用基因芯片primeview、Ingenuity通路分析及生物信息学分析,结合免疫共沉淀、蛋白稳定性实验和泛素化分析阐明CDCA2的下游基因和调控机制。

主要发现

  • CDCA2在黑色素瘤组织中高表达,且CDCA2水平与肿瘤分期和不良预后正相关。
  • CDCA2下调通过诱导G1/S期阻滞和凋亡显著减少细胞迁移和增殖。
  • CDCA2敲低在体内抑制肿瘤生长和Ki67表达。
  • CDCA2通过作用于SMAD特异性E3泛素蛋白连接酶1抑制泛素依赖性Aurora激酶A(AURKA)蛋白降解。
  • AURKA下调抑制黑色素瘤细胞增殖和迁移并促进凋亡,AURKA高表达提示黑色素瘤患者生存期差,且AURKA敲低限制了CDCA2过表达诱导的增殖和迁移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant melanoma is one of the most aggressive types of malignant skin cancer. CDCA2 is of great significance in many tumours, but its role in melanoma is unclear. METHODS: CDCA2 expression in melanoma samples and benign melanocytic naevus tissues was detected by GeneChip and bioinformatics analysis as well as immunohistochemistry. The gene expression in melanoma cells was detected by quantitative PCR detecting system and Western blot. Melanoma models with gene knockdown or overexpression were constructed in vitro, and the effects of gene knockdown or overexpression on melanoma cell phenotype and tumour growth were evaluated by celigo cell counting, transwell, wound healing, flow cytometry and subcutaneous nude mouse tumour models. GeneChip primeview, Ingenuity pathway analysis and bioinformatics analysis combined with co-immunoprecipitation, protein stability experiments and ubiquitination analysis were performed to demonstrate the downstream genes and regulatory mechanism of CDCA2. RESULTS: CDCA2 was highly expressed in melanoma tissues, and CDCA2 level was positively correlated with tumour stage and poor prognosis. CDCA2 downregulation significantly reduced cell migration and proliferation by inducing G1/S phase arrest and apoptosis. CDCA2 knockdown suppressed tumour growth and Ki67 expression in vivo. Mechanistically, CDCA2 inhibited ubiquitin-dependent Aurora kinase A (AURKA) protein degradation by acting on SMAD specific E3 ubiquitin protein ligase 1. AURKA downregulation inhibited melanoma cell proliferation and migration and promoted apoptosis. High expression of AURKA implied poor survival in melanoma patients. Moreover, AURKA knockdown constricted CDCA2 overexpression-induced proliferation and migration. CONCLUSION: CDCA2, which was upregulated in melanoma, enhanced AURKA protein stability by inhibiting SMAD specific E3 ubiquitin protein ligase 1-mediated AURKA ubiquitination, thus playing a carcinogenic role in melanoma progression.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sun W, Jin Y, Wei C, et al. CDCA2 promotes melanoma progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A. Eur J Cancer. 2023. PMID: 37196484. doi:10.1016/j.ejca.2023.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。